将血蛋白质组学与全基因组关联数据集成,以确定炎症性肠病的新型药物标
Zhongyuan Bai1, Jiawei Hao2, Miaoran Chen2
1First Clinical Medical School, Shanxi Medical University, Taiyuan, China.
Scientific reports
|July 15, 2024
概括
这项研究整合了遗传和蛋白质组数据,以确定炎症性肠病 (IBD) 的新疗法标,包括克罗恩病 (CD) 和性结肠炎 (UC). 这些发现突出了CADM2等特定蛋白质作为IBD治疗的潜在药物点.
科学领域:
- 遗传学 是一个遗传学.
- 蛋白质组学是指蛋白质组学.
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病 (IBD),包括克罗恩病 (CD) 和性结肠炎 (UC),是一种具有复杂遗传基础的慢性疾病.
- 全基因组关联研究 (GWAS) 已经确定了IBD的众多遗传风险位置,但它们对蛋白质水平和治疗潜力的功能影响仍然不清楚.
研究的目的:
- 通过整合遗传和蛋白质基因数据来研究IBD的病原性.
- 确定用于IBD,CD和UC的治疗干预的新型蛋白质标.
主要方法:
- 对IBD,UC和CD的GWAS数据 (N=25,305) 与来自ARIC研究的人类血液蛋白质组数据 (N=7213) 的系统整合.
- 应用全蛋白质组关联研究 (PWAS),门德尔随机化 (MR) 和贝叶斯同位分析来识别与疾病相关的蛋白质.
- 利用DGIdb在已识别的基因中识别潜在的药物标.
主要成果:
- 与IBD,UC和CD相关的遗传变异影响了几种cis调节血蛋白的丰富性.
- 具体来说,IBD,UC和CD分别与五种,三种和两种蛋白质相关,包括CADM2,RIPK2和MST1.
- CADM2被确定为IBD和UC的共同蛋白质标.
- 确定了一种药物和五种可使用药物的向基因.
结论:
- 这种综合性遗传和蛋白质组分析成功地确定了涉及IBD病变的关键蛋白质.
- 已识别的蛋白质,如CADM2,为未来的功能研究提供了有希望的线索.
- 这些发现为IBD,CD和UC的临床管理提供了潜在的新药标.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
125
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
128
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
128
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
114
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
114
Inflammatory Bowel Disease I: Ulcerative Colitis
160
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
160


